CC
REGN icon

Cognios Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Cognios Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,579
Closed -$1.26M – 174
2020
Q1 		$1.26M Buy
+2,579
New +$1.06M 0.63% 73

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cognios Capital's REGN Position: Q2 2020 in Review

Cognios Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2020, closing a stake of 2,579 shares — an estimated $1.26M sold.

Cognios Capital first reported a position in REGN in Q1 2020 and held it in 1 quarter. The position peaked at $1.26M in Q1 2020. 933 funds tracked by Wall St. Rank hold REGN as of Q2 2020.

  • Cognios Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Cognios Capital sold 2,579 Regeneron Pharmaceuticals shares in Q2 2020, an estimated $1.26M.
  • Cognios Capital first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Cognios Capital's Regeneron Pharmaceuticals position peaked at $1.26M in Q1 2020.
  • 933 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2020.

Based on Cognios Capital's 13F filing for Q2 2020.